NEJM highlights GLP-1 receptor agonists for diabetes and obesity with cardiovascular and kidney benefits, while Eric Topol and Keith Siau amplify the same NEJM review as a key reference point.
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity
trials have shown reductions in cardiovascular risk and slowing of kidney failure.
Adverse events are mostly gastrointestinal.
A new review of the GLP-1 receptor drugs
GLP1 agonists - April 2026 NEJM review
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare